HENLIUS(02696): Hanli Kang (Rituximab Injection) supplementary application for new indications approved by the National Medical Products Administration.
Fosun Pharma (02696) announced that recently, the company's independently developed Hanlikang (Rituximab Injection) ("Hanlikang") has received approval from the National Medical Products Administration ("NMPA") for supplementary applications for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in adults with a combination of Bevacizumab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone; and for the treatment of relapsed or refractory DLBCL in adults who are not suitable for hematopoietic stem cell transplant with a combination of Bendamustine and Bevacizumab.
HENLIUS (02696) announced that recently, the company's self-developed product, Hanlicon (rituximab injection) ("Hanlicon"), has obtained approval from the National Medical Products Administration ("NMPA") for supplementary applications for the addition of two new indications: the combination of veliparib monotherapy, cyclophosphamide, doxorubicin, and prednisone for the treatment of untreated diffuse large B-cell lymphoma (DLBCL) in adults; and the combination of bendamustine and veliparib monotherapy for the treatment of relapsed or refractory DLBCL in adults who are not suitable for hematopoietic stem cell transplantation.
Related Articles
Guotai Haitong: The foundation of the gold bull market is still in place. Short-term adjustments and fluctuations can still provide good allocation opportunities.
CITIC SEC: Price differentiation in commodities continues in Q2 2026, remains optimistic about the performance of chemical products.
NIO (09866) Li Bin: Standardization of battery cells and normalization of chips will provide the industry with an opportunity to reduce costs by over 100 billion yuan.
Guotai Haitong: The foundation of the gold bull market is still in place. Short-term adjustments and fluctuations can still provide good allocation opportunities.
CITIC SEC: Price differentiation in commodities continues in Q2 2026, remains optimistic about the performance of chemical products.
NIO (09866) Li Bin: Standardization of battery cells and normalization of chips will provide the industry with an opportunity to reduce costs by over 100 billion yuan.
RECOMMEND
